Intranasal Corticosteroids Market Expansion Outlook: $9.07 Billion in 2029

Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.

What Is the Projected CAGR for the Intranasal Corticosteroids Market from 2024 to 2025?
The market for intranasal corticosteroids has significantly expanded in the past few years. It's projected to increase from $6.29 billion in 2024 to $6.78 billion in 2025, witnessing a compound annual growth rate (CAGR) of 7.8%. The historic growth can be traced back to the increasing cases of allergic rhinitis, the rising frequency of chronic sinusitis, heightened awareness of non-oral therapies, an increase in its usage for pediatric allergic conditions, and the wider availability of intranasal products over the counter.

What are the Expected Market Size and CAGR for Intranasal Corticosteroids by 2029?
Expectations are high for the intranasal corticosteroids market to demonstrate robust growth in the coming years, expanding to $9.07 billion by 2029 with a compound annual growth rate (CAGR) of 7.6%. This predicted growth in the forecast period can be linked to an increased emphasis on minimally invasive treatments, a rising incidence of allergies linked to climate change, a heightened preference for self-administered therapies, a broader acceptance of combined intranasal therapies, and the rise of digital health aids for managing allergies. The forthcoming period is set to see trends such as the inclusion of smart gadgets for monitoring dosage, advancements in preservative-free nasal sprays, advancements in child-friendly formulations, the development of steroid-free supplementary therapies, and the integration of e-health platforms to monitor treatments.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/intranasal-corticosteroids-global-market-report

Which Factors Are Driving the Global Intranasal Corticosteroids Market Expansion?
The escalating incidence of allergic rhinitis is projected to fuel the expansion of the intranasal corticosteroids market in the future. Allergic rhinitis is an allergic response that triggers inflammation in the nasal lining, usually caused by allergens present in the air like pollen, dust mites, mold or pet fur. The mounting incidence of allergic rhinitis is predominantly attributed to the rise in environmental pollution, exposing people to airborne allergens and irritants that provoke allergies in the nasal lining. Intranasal corticosteroids are effective in treating allergic rhinitis by reducing nasal lining inflammation, thus decreasing symptoms such as sneezing, congestion, and nasal discharge. For example, in October 2023, per the National Library of Medicine, a biomedical library based in the United States, allergic rhinitis affects over 400 million people globally, with estimates on prevalence rates being at 10%-30% amongst adults and over 40% in kids. Consequently, the rising incidence of allergic rhinitis is propelling the intranasal corticosteroid market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25799&type=smp

Which Segment Currently Holds the Largest Share of the Intranasal Corticosteroids Market?
The intranasal corticosteroids market covered in this report is segmented -

1) By Drug Types: Prescribed Drugs, Over-The-Counter Drugs
2) By Application: Allergic Rhinitis, Nasal Polyps, Sinusitis, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel
4) By End User: Hospitals, Clinics, Homecare, Healthcare Providers

Subsegments:
1) By Prescribed Drugs: Fluticasone Propionate, Mometasone Furoate, Budesonide, Beclomethasone Dipropionate, Ciclesonide
2) By Over-The-Counter Drugs: Triamcinolone Acetonide, Fluticasone Furoate, Budesonide Over-The-Counter Drugs

Which Major Trends Are Shaping the Future of the Intranasal Corticosteroids Industry?
Companies dominating the intranasal corticosteroids sector are certain on bringing forth novel formulations such as nasal sprays. Their aim is to promote targeted delivery and elevate patient adherence. Nasal sprays are liquid drugs, administered straight into the nasal passageways using a spray applicator to alleviate ailments like allergies, congestion or inflammation. They permit speedy drug assimilation via the nasal mucosa, providing swift relief with negligible systemic impacts. In March 2024, for example, OptiNose Inc., domiciled in the United States, secured the approval of the U.S. Food and Drug Administration (FDA) for their product named XHANCE. This unprecedented treatment is solely indicated for adults suffering from chronic rhinosinusitis (CRS) devoid of nasal polyps. XHANCE employs a unique exhalation delivery system for the drug to penetrate deep into the nasal chambers, effectively alleviating CRS with or without the presence of nasal polyps in adults. Each application delivers 93 mcg of fluticasone propionate. The device requires the user to exhale into a mouthpiece while discharging the spray into the nostril, assuring meticulous delivery and amplified symptom alleviation.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25799&type=smp

Which Key Players Dominate the Intranasal Corticosteroids Industry Globally?
Major companies operating in the intranasal corticosteroids market are GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Haleon plc, Intas Pharmaceuticals Limited, Organon Pharma (UK) Limited, Sun Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Limited, Cipla Ltd., Hikma Pharmaceuticals plc, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, OptiNose US Inc., Taro Pharmaceutical Industries Ltd., Maya Biotech Private Limited, AdvaCare Pharma USA, Lupin Ltd., Xenone Healthcare Private Limited.

What Are the Fastest-Growing Regions in the Intranasal Corticosteroids Market?
North America was the largest region in the intranasal corticosteroids market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intranasal corticosteroids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Reach Out to Us
Speak With Our Expert:Saumya Sahay,
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267,
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.